Empagliflozin is a once-daily medicine for adults with type 2 diabetes, heart failure, or chronic kidney disease. It supports blood glucose control while helping reduce cardiovascular and kidney risks by increasing glucose and sodium excretion through the urine.
Empagliflozin is an oral SGLT2 inhibitor used in adults with type 2 diabetes, heart failure, or chronic kidney disease. It suits people who need glucose control alongside proven cardiovascular and kidney benefits. The medicine increases glucose removal through urine by acting on the kidneys.
Empagliflozin tablets contain empagliflozin, a medicine from the sodium-glucose co-transporter 2 inhibitor, or SGLT2 inhibitor, class. SGLT2 is a protein in the kidneys that normally reabsorbs glucose from urine back into the bloodstream. Blocking this protein allows part of that glucose to leave the body in urine.
This mechanism differs from insulin. Empagliflozin does not force the pancreas to release more insulin, so low blood glucose is less likely when it is used alone. The risk rises when it is combined with insulin or a sulfonylurea such as gliclazide.
Empagliflozin is taken orally once daily, at the prescribed strength. It can be taken with or without food. Taking it at roughly the same time each day helps maintain a reliable routine.
Use the prescribed regimen consistently:
The effect on glucose may be measurable before a person feels any different.
HbA1c reflects average glucose exposure over about two to three months, so laboratory follow-up is more informative than judging the medicine by day-to-day feelings.
Empagliflozin inhibits SGLT2 in the kidneys, reducing glucose and sodium reabsorption. This increases the excretion of glucose and sodium in the urine, supporting blood glucose control and reducing pressure inside the kidney filters.
Empagliflozin may be prescribed for:
Empagliflozin is one option within a broader treatment plan. The right choice depends on glucose targets, kidney function, heart failure, body weight goals, other medicines, and tolerance.
| Treatment approach | Main action | Typical place in treatment |
|---|---|---|
| Empagliflozin | Increases urinary glucose and sodium excretion through SGLT2 inhibition | Type 2 diabetes, heart failure, chronic kidney disease |
| Metformin | Reduces liver glucose production and improves insulin sensitivity | Often an initial medicine for type 2 diabetes |
| GLP-1 receptor agonists | Increase glucose-dependent insulin release and reduce appetite | Type 2 diabetes with a need for greater weight reduction or cardiovascular risk reduction |
Metformin mainly targets glucose production by the liver. Empagliflozin works through the kidneys and also has evidence for heart failure and kidney protection. GLP-1 receptor agonists can produce greater average weight loss, though nausea and vomiting are more common early in treatment.
KDIGO’s 2024 chronic kidney disease guideline recommends SGLT2 inhibitors for many adults with chronic kidney disease, including people with or without diabetes in defined clinical settings [1]. Kidney function and urine albumin results help guide whether this approach is suitable.
Empagliflozin is not for you if you have a known allergy to empagliflozin or a tablet ingredient. It is also not used for type 1 diabetes because of the heightened risk of diabetic ketoacidosis.
Extra caution is needed with dehydration, recurrent genital infections, recurrent urinary infections, severe acute illness, and a history of ketoacidosis. Kidney function should be assessed at intervals because suitability and expected glucose-lowering effect change as kidney function declines.
Important interaction considerations include:
Pregnancy and breastfeeding require individual medical review because treatment goals and medicine choices may change. Acute vomiting, diarrhoea, fever, or inability to drink normally also requires a clear sick-day plan from the prescriber.
This medicine may not be suitable if you have had an allergic reaction to empagliflozin or its ingredients, have type 1 diabetes, are dehydrated, or have repeated genital or urinary infections. Speak with your clinician before taking it if you have severe illness, a previous episode of ketoacidosis, are pregnant or breastfeeding, or take insulin, sulfonylureas, diuretics, blood-pressure medicines, or lithium.
Most people tolerate empagliflozin well. Increased urination is expected from its mechanism. Thirst, mild dehydration, dizziness, and genital fungal infections can also occur. Risk varies with kidney function, age, fluid intake, and other medicines. Persistent or troublesome effects should be discussed with the prescriber rather than managed by changing the dose independently.
Genital yeast infections may cause itching, redness, soreness, unusual discharge, or discomfort during urination. Urinary tract infections can cause burning urine, urgency, lower abdominal pain, fever, or flank pain. Early treatment matters because symptoms can worsen quickly.
Some effects need urgent attention:
The EMA identifies genital infections, urinary infections, volume depletion, and ketoacidosis as key safety considerations for empagliflozin and other SGLT2 inhibitors [2].
The most frequent problem is treating empagliflozin as a glucose-only tablet. Heart and kidney benefits depend on steady use over time, even when home glucose readings look stable.
Other mistakes include:
In clinical practice, doctors often value empagliflozin because it addresses more than HbA1c. For a person with type 2 diabetes and heart failure, a treatment that also reduces heart failure hospitalisation risk can change the conversation around glucose management.
Doctors also stress that the medication’s diuretic-like effect is mild but real. A patient already taking a loop diuretic for ankle swelling may need fluid status, blood pressure, and kidney function reviewed after treatment begins. People who feel well should still attend planned blood and kidney tests.
The EMPA-KIDNEY trial, published in The New England Journal of Medicine in 2023, found that empagliflozin reduced the risk of kidney disease progression or cardiovascular death in a broad chronic kidney disease population [3]. The benefit was clinically meaningful, yet the medicine still requires attention to hydration and infection symptoms.
Empagliflozin is used in adults with type 2 diabetes and may also be used for heart failure or chronic kidney disease when clinically appropriate. The WHO includes SGLT2 inhibitors among important medicines for noncommunicable disease care because they address diabetes-related cardiovascular and renal risk. FDA prescribing information published in 2023 also describes uses beyond glucose control in defined adult populations. Treatment selection depends on kidney function, medical history, and other medicines.
Urinary glucose excretion begins after treatment starts, though the full HbA1c effect is assessed over several weeks to months. HbA1c is a longer-term measure, so a blood test is more meaningful than judging effectiveness after a few days. The FDA’s 2023 prescribing information supports regular glycaemic monitoring during treatment. Symptoms such as thirst or fatigue can have many causes and are not reliable markers by themselves.
Empagliflozin alone has a low hypoglycaemia risk because its glucose-lowering action does not directly stimulate insulin release. Low glucose becomes more likely when it is combined with insulin or a sulfonylurea. EMA safety information updated in 2024 advises attention to this combination risk. Sweating, shaking, hunger, palpitations, and confusion need prompt glucose checking and treatment according to an established hypoglycaemia plan.
The medicine increases glucose in urine, which can create conditions that favour yeast growth around the genital area. This is a known class effect of SGLT2 inhibitors rather than a sign that the medicine has stopped working. The EMA's 2024 product information describes genital mycotic infection as a recognised adverse effect. Prompt treatment and good hydration usually help prevent a minor infection becoming prolonged or recurrent.
Nausea, vomiting, abdominal pain, unusual tiredness, confusion, and fast or deep breathing are warning signs. Ketoacidosis can occur with glucose levels that are not markedly elevated, so a normal-looking meter result should not delay urgent assessment. The FDA highlighted this risk in SGLT2 inhibitor safety communications issued in 2015 and retained related warnings in later prescribing information. Acute illness, fasting, surgery, substantial alcohol intake, and sudden insulin reduction can increase risk.
Empagliflozin can slow chronic kidney disease progression in suitable patients by changing pressure within the kidney filters and reducing harmful hyperfiltration. The 2023 EMPA-KIDNEY study in The New England Journal of Medicine reported fewer kidney-progression or cardiovascular-death events with empagliflozin than with placebo. Kidney tests may show a small early change in estimated filtration rate before the longer-term protective pattern becomes clear. Planned monitoring helps clinicians interpret this correctly.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
My fasting readings improved steadily, and I lost a small amount of weight without changing everything at once. I noticed more trips to the bathroom in the first week, then it became manageable after I moved the tablet to breakfast time.
I was taking it alongside treatment for heart failure. My ankle swelling was less troublesome after several weeks, although my doctor monitored my blood pressure because I felt light-headed when standing up too quickly.
The glucose improvement was good, but I developed itching and soreness that turned out to be a fungal infection. It was treated, and I learned not to ignore early symptoms or cut back on fluids.
I did not feel a dramatic change, which was frustrating at first. My HbA1c and kidney results gave a clearer picture than how I felt day to day, and that helped me stay consistent.
